Patrick Haley Sells 67,814 Shares of Exelixis (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick Haley sold 67,814 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $43.52, for a total value of $2,951,265.28. Following the sale, the executive vice president owned 381,908 shares in the company, valued at approximately $16,620,636.16. This trade represents a 15.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Exelixis Stock Performance

NASDAQ EXEL opened at $44.16 on Friday. The business’s 50 day moving average price is $43.83 and its 200-day moving average price is $41.15. Exelixis, Inc. has a fifty-two week low of $32.38 and a fifty-two week high of $49.62. The company has a market cap of $11.47 billion, a P/E ratio of 15.94, a P/E/G ratio of 1.00 and a beta of 0.42.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.20. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The company had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. During the same period last year, the company earned $0.55 earnings per share. Exelixis’s revenue was up 5.6% on a year-over-year basis. As a group, equities analysts predict that Exelixis, Inc. will post 2.04 EPS for the current year.

Wall Street Analysts Forecast Growth

EXEL has been the subject of several recent analyst reports. Wall Street Zen lowered Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Wells Fargo & Company raised their price target on Exelixis from $30.00 to $35.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 11th. Citigroup downgraded Exelixis from a “market outperform” rating to an “underperform” rating in a research report on Monday, January 5th. Truist Financial set a $51.00 target price on Exelixis in a research report on Wednesday, January 14th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $47.11.

Hedge Funds Weigh In On Exelixis

A number of hedge funds and other institutional investors have recently modified their holdings of EXEL. Farallon Capital Management LLC lifted its holdings in Exelixis by 21.6% during the third quarter. Farallon Capital Management LLC now owns 19,501,500 shares of the biotechnology company’s stock worth $805,412,000 after buying an additional 3,466,000 shares during the period. AQR Capital Management LLC lifted its stake in shares of Exelixis by 48.8% during the 4th quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock worth $598,647,000 after purchasing an additional 4,477,029 shares during the last quarter. Geode Capital Management LLC boosted its position in Exelixis by 0.4% during the second quarter. Geode Capital Management LLC now owns 7,445,469 shares of the biotechnology company’s stock valued at $328,196,000 after purchasing an additional 28,289 shares in the last quarter. Invesco Ltd. grew its stake in Exelixis by 1.6% in the fourth quarter. Invesco Ltd. now owns 6,054,743 shares of the biotechnology company’s stock valued at $265,379,000 after purchasing an additional 94,218 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its holdings in Exelixis by 42.9% in the second quarter. Arrowstreet Capital Limited Partnership now owns 5,262,643 shares of the biotechnology company’s stock worth $231,951,000 after purchasing an additional 1,580,567 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors.

Key Exelixis News

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q4 earnings beat: Exelixis reported $0.94 EPS vs. $0.74 expected and showed y/y revenue growth (Q4 revenue $598.7M), which supports earnings momentum and margin strength. MarketBeat EXEL summary
• Positive Sentiment: Institutional / analyst backdrop is broadly constructive: multiple funds have added or increased stakes and several analysts have maintained or slightly raised targets (consensus target ~ $47.11), which leaves upside if execution/clinical data remain favorable. Analyst & institutional notes
• Neutral Sentiment: Short interest note appears anomalous — the reported February short interest shows 0 shares (short‑interest ratio 0.0 days), likely a data reporting artifact and not informative for positioning. (Source: short‑interest entry)
• Neutral Sentiment: Technical / valuation context: market cap ~ $11.5B, P/E ~16, 50‑day sma ≈ $43.8 and 200‑day sma ≈ $41 — the stock sits between short‑ and long‑term averages so momentum could swing with new catalysts. Key metrics
• Negative Sentiment: Large executive/insider selling this week: EVP Patrick Haley sold 67,814 shares (~$2.95M on Feb 17). Such large insider disposals can create negative optics about timing or liquidity needs. Haley SEC filing
• Negative Sentiment: Repeated CFO sales: Christopher Senner disclosed two sales (34,278 on Feb 13 and 30,617 on Feb 17) totaling roughly $2.8M, which amplifies negative insider‑selling optics. CFO SEC filings
• Negative Sentiment: Director-level reductions: Director Bob Oliver sold 30,250 shares (~$1.33M; ~59% reduction) and other insiders (SVP Brenda Hefti, Director Sue Eckhardt) also sold smaller blocks — combined insider sales this week approximate $8–9M, which likely pressured sentiment. Oliver SEC filing Hefti SEC filing Eckhardt SEC filing

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.